The US Supreme Court is set to hear one case this term that could bolster the biopharma industry’s ability to challenge US Food and Drug Administration rules and it is likely to take up another case that would undermine industry's reliance on agency decisions.
The biopharmaceutical industry is in FDA's corner in the latter litigation, in which the Alliance for Hippocratic Medicine, a group...





